bioAffinity Technologies, Inc. (BIAF) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
22211 West Interstate 10
San Antonio, TX 78257
United States of America (the)
Phone
210 698 5334
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
57
First IPO Date
September 01, 2022
| Name | Title | Pay | Year Born |
| Maria Zannes | Founder, President, Chief Executive Officer & Director | 368,994 | 1956 |
| Steven Girgenti | Founder & Executive Chairman of the Board | 167,401 | 1946 |
| James Michael Edwards | Chief Financial Officer | 330,111 | 1967 |
| Xavier T. Reveles | Chief Operating Officer | 0 | 1969 |
| Gordon Downie | Chief Medical Officer | 0 | N/A |
| William Bauta | Chief Science Officer | 0 | N/A |
| Dallas J. Coleman | Vice President of sales | 0 | N/A |
| Timothy Zannes | Executive Vice President, Secretary & General Counsel | 0 | 1954 |
| Julie Anne Overton | Director of Communications | 0 | N/A |
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.